Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Anticoagulants Show Superior Efficacy Over Antiplatelet Agents After TAVI

2w ago September 1, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

The ACASA-TAVI trial demonstrated that anticoagulants are more effective than antiplatelet agents in preventing clot formation after transcatheter aortic valve implantation (TAVI), with no safety concerns. This finding, presented at ESC Congress 2026 and published in JAMA, could influence medical practices in Iran regarding post-TAVI care.

🔍 Quick Context Guide
💡 Bottom Line: The ACASA-TAVI trial's findings could significantly influence post-operative care for TAVI patients, including in Iran.

👥 Key Players

ESC Congress MENTIONED
Medical conference organizing body
"They are a key platform for presenting significant medical research findings that can influence clinical practices globally, including in Iran."
JAMA MENTIONED
Medical journal
"Publishing in JAMA lends credibility to the research and can impact medical guidelines and practices in Iran and beyond."

📰 What Happened

The ACASA-TAVI trial found that anticoagulants are more effective than antiplatelet agents in preventing clot formation after transcatheter aortic valve implantation (TAVI), with no safety issues reported. This was presented at the ESC Congress 2026 and published in JAMA.

  • Anticoagulation therapy showed superior efficacy in reducing clot formation on new valves post-TAVI.
  • The findings were presented at a major medical conference and published in a leading medical journal.

💡 Why It Matters

🇮🇷 For Iran: This finding could lead to changes in post-TAVI care protocols in Iran, potentially improving patient outcomes in cardiovascular health.
🌍 Regional: Improved treatment protocols could enhance healthcare standards across the region, influencing neighboring countries' practices.
🌐 International: The results may prompt reevaluation of anticoagulation versus antiplatelet therapy in post-surgical care internationally, impacting guidelines and practices.

📚 Background

Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure for patients with aortic valve stenosis. Anticoagulants and antiplatelet agents are both used to prevent clot formation after such procedures.

Cardiovascular health Minimally invasive surgery
📡 Source: NEUTRAL
📊 Confidence: 70%
The information comes from a peer-reviewed journal and a reputable medical conference, indicating a high level of reliability.

After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety. This was the main finding of the ACASA-TAVI trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in JAMA.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →